MEKTOVI is indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by …

Mar 26, 2024 · Mektovi (binimetinib) is an oral kinase inhibitor that may be used in combination with encorafenib for the treatment of adults with unresectable or metastatic melanoma or …

Binimetinib, sold under the brand name Mektovi, is an anti-cancer medication used to treat various cancers. [4] Binimetinib is a selective inhibitor of MEK, a central kinase in the tumor …

MEKTOVI® (binimetinib) This product information is intended only for residents of the United States. for Consumers: MEKTOVI U.S. Medication Guide; MEKTOVI - U.S. Medical …

See full prescribing information for MEKTOVI. MEKTOVI is a kinase inhibitor indicated: Melanoma. The recommended dose is 45 mg orally twice daily in combination with …

MEKTOVI is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as...

MEKTOVI is a prescription medicine used: • in combination with a medicine called encorafenib to treat people with a type of skin cancer called melanoma: o that has spread to other parts of the …

Find patient medical information for Mektovi oral on WebMD including its uses, side effects and safety, interactions, pictures, warnings and user ratings.

Mar 6, 2024 · Mektovi is a brand-name oral tablet that’s prescribed for certain types of cancer. Mektovi contains the active ingredient binimetinib. Mektovi is FDA approved to treat the …

Mar 27, 2025 · Mektovi (binimetinib) is a kinase inhibitor indicated, in combination with encorafenib, for the treatment of patients with unresectable or metastatic melanoma with a …